CL2014001349A1 - Composición que comprende una inmunoglobulina con dos dominios variables dirigida contra il-1a/ß o una porción del antígeno de esta, la cual tiene características farmacocinéticas específicas; y uso de la composición para tratar o prevenir osteoartritis, dolor o un trastorno donde la actividad de il-1 resulta perjudicial. - Google Patents
Composición que comprende una inmunoglobulina con dos dominios variables dirigida contra il-1a/ß o una porción del antígeno de esta, la cual tiene características farmacocinéticas específicas; y uso de la composición para tratar o prevenir osteoartritis, dolor o un trastorno donde la actividad de il-1 resulta perjudicial.Info
- Publication number
- CL2014001349A1 CL2014001349A1 CL2014001349A CL2014001349A CL2014001349A1 CL 2014001349 A1 CL2014001349 A1 CL 2014001349A1 CL 2014001349 A CL2014001349 A CL 2014001349A CL 2014001349 A CL2014001349 A CL 2014001349A CL 2014001349 A1 CL2014001349 A1 CL 2014001349A1
- Authority
- CL
- Chile
- Prior art keywords
- composition
- immunoglobulin
- antigen
- pain
- disorder
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/46—Hybrid immunoglobulins
- C07K16/468—Immunoglobulins having two or more different antigen binding sites, e.g. multifunctional antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/04—Antipruritics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/14—Drugs for dermatological disorders for baldness or alopecia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/32—Alcohol-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/06—Antianaemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
- C07K16/244—Interleukins [IL]
- C07K16/245—IL-1
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/64—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising a combination of variable region and constant region components
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Diabetes (AREA)
- Dermatology (AREA)
- Hematology (AREA)
- Pulmonology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Oncology (AREA)
- Cardiology (AREA)
- Pain & Pain Management (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Rheumatology (AREA)
- Communicable Diseases (AREA)
- Urology & Nephrology (AREA)
- Psychology (AREA)
- Heart & Thoracic Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Addiction (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201161562245P | 2011-11-21 | 2011-11-21 | |
US201161562728P | 2011-11-22 | 2011-11-22 |
Publications (1)
Publication Number | Publication Date |
---|---|
CL2014001349A1 true CL2014001349A1 (es) | 2014-10-10 |
Family
ID=48470408
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CL2014001349A CL2014001349A1 (es) | 2011-11-21 | 2014-05-22 | Composición que comprende una inmunoglobulina con dos dominios variables dirigida contra il-1a/ß o una porción del antígeno de esta, la cual tiene características farmacocinéticas específicas; y uso de la composición para tratar o prevenir osteoartritis, dolor o un trastorno donde la actividad de il-1 resulta perjudicial. |
Country Status (24)
Country | Link |
---|---|
US (1) | US20140348838A1 (es) |
EP (1) | EP2782601A4 (es) |
JP (1) | JP2015500206A (es) |
KR (1) | KR20140097430A (es) |
CN (1) | CN104203278A (es) |
AU (1) | AU2012340878A1 (es) |
BR (1) | BR112014012121A2 (es) |
CA (1) | CA2856582A1 (es) |
CL (1) | CL2014001349A1 (es) |
CO (1) | CO6990666A2 (es) |
CR (1) | CR20140279A (es) |
DO (1) | DOP2014000111A (es) |
EC (1) | ECSP14005992A (es) |
GT (1) | GT201400099A (es) |
HK (1) | HK1202444A1 (es) |
IL (1) | IL232674A0 (es) |
IN (1) | IN2014CN04582A (es) |
MX (1) | MX2014006160A (es) |
PE (1) | PE20141941A1 (es) |
PH (1) | PH12014501138A1 (es) |
RU (1) | RU2014125220A (es) |
SG (1) | SG11201402533YA (es) |
WO (1) | WO2013078135A2 (es) |
ZA (1) | ZA201404481B (es) |
Families Citing this family (21)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
TWI465250B (zh) | 2009-08-29 | 2014-12-21 | Abbvie Inc | 治療用之dll4結合蛋白質 |
EP2542582A4 (en) | 2010-03-02 | 2013-12-04 | Abbvie Inc | THERAPEUTIC PROTEINS LINKING TO DLL4 |
CA2807014A1 (en) | 2010-08-03 | 2012-02-09 | Abbvie Inc. | Dual variable domain immunoglobulins and uses thereof |
RU2015134562A (ru) * | 2011-02-08 | 2018-12-24 | Эббви Инк. | Лечение остеоартрита и боли |
AU2013337775B2 (en) | 2012-11-01 | 2017-03-30 | Abbvie Inc. | Anti-VEGF/DLL4 dual variable domain immunoglobulins and uses thereof |
WO2015084883A2 (en) | 2013-12-02 | 2015-06-11 | Abbvie, Inc. | Compositions and methods for treating osteoarthritis |
WO2015138337A1 (en) | 2014-03-09 | 2015-09-17 | Abbvie, Inc. | Compositions and methods for treating rheumatoid arthritis |
US20160002326A1 (en) | 2014-06-10 | 2016-01-07 | Abbvie Inc. | Compositions and methods for treating rheumatoid arthritis |
US20160000936A1 (en) | 2014-06-10 | 2016-01-07 | Abbvie Inc. | Biomarkers for inflammatory disease and methods of using same |
US10093733B2 (en) | 2014-12-11 | 2018-10-09 | Abbvie Inc. | LRP-8 binding dual variable domain immunoglobulin proteins |
US10399874B2 (en) | 2014-12-11 | 2019-09-03 | Lg Electronics Inc. | Drinking water supply device and method of controlling a drinking water supply device |
US10031533B2 (en) | 2014-12-11 | 2018-07-24 | Lg Electronics Inc. | Drinking water supply device |
US10077544B2 (en) | 2014-12-11 | 2018-09-18 | Lg Electronics Inc. | Drinking water supply device |
KR101629334B1 (ko) * | 2015-01-27 | 2016-06-10 | 엘지전자 주식회사 | 음용수 공급장치 및 이의 제어방법 |
US20160244520A1 (en) | 2015-01-24 | 2016-08-25 | Abbvie Inc. | Compositions and methods for treating psoriatic arthritis |
TW201710286A (zh) | 2015-06-15 | 2017-03-16 | 艾伯維有限公司 | 抗vegf、pdgf及/或其受體之結合蛋白 |
KR20180134880A (ko) * | 2016-03-09 | 2018-12-19 | 슈 생-쥐스땡 | 주산기 이환율 및/또는 사망률을 감소시키는 방법 |
CN106344935B (zh) * | 2016-10-11 | 2020-01-07 | 武汉大学 | Toll样蛋白相互作用蛋白在治疗血管损伤后再狭窄中的功能和应用 |
CN110680905A (zh) * | 2019-10-24 | 2020-01-14 | 内蒙古医科大学第二附属医院 | Tslp在制备治疗腰椎间盘突出药物中的应用 |
CN114113624A (zh) * | 2020-08-28 | 2022-03-01 | 香港城市大学深圳研究院 | 利用免疫球蛋白关联蛋白质组开发疾病标志物的方法及装置 |
CN116930385B (zh) * | 2023-08-08 | 2024-02-20 | 北京爱思益普生物科技股份有限公司 | 一种高盐浓度制剂中化合物浓度的测定方法 |
Family Cites Families (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR20080074231A (ko) * | 2000-06-29 | 2008-08-12 | 아보트 러보러터리즈 | 이중 특이성 항체 및 이의 제조 및 사용 방법 |
EP2114443A4 (en) * | 2006-12-29 | 2011-08-10 | Abbott Lab | IL-1A / IL-1B ANTIBODY WITH DOUBLE SPECIFICITY |
EP2571532B1 (en) * | 2010-05-14 | 2017-05-03 | Abbvie Inc. | Il-1 binding proteins |
-
2012
- 2012-11-19 AU AU2012340878A patent/AU2012340878A1/en not_active Abandoned
- 2012-11-19 CA CA2856582A patent/CA2856582A1/en not_active Abandoned
- 2012-11-19 BR BR112014012121A patent/BR112014012121A2/pt not_active IP Right Cessation
- 2012-11-19 CN CN201280067294.9A patent/CN104203278A/zh active Pending
- 2012-11-19 US US14/359,808 patent/US20140348838A1/en not_active Abandoned
- 2012-11-19 RU RU2014125220/15A patent/RU2014125220A/ru not_active Application Discontinuation
- 2012-11-19 EP EP12851661.4A patent/EP2782601A4/en not_active Withdrawn
- 2012-11-19 WO PCT/US2012/065872 patent/WO2013078135A2/en active Application Filing
- 2012-11-19 JP JP2014542551A patent/JP2015500206A/ja active Pending
- 2012-11-19 SG SG11201402533YA patent/SG11201402533YA/en unknown
- 2012-11-19 PE PE2014000722A patent/PE20141941A1/es not_active Application Discontinuation
- 2012-11-19 KR KR1020147017117A patent/KR20140097430A/ko not_active Application Discontinuation
- 2012-11-19 MX MX2014006160A patent/MX2014006160A/es unknown
-
2014
- 2014-05-18 IL IL232674A patent/IL232674A0/en unknown
- 2014-05-21 GT GT201400099A patent/GT201400099A/es unknown
- 2014-05-21 PH PH12014501138A patent/PH12014501138A1/en unknown
- 2014-05-21 DO DO2014000111A patent/DOP2014000111A/es unknown
- 2014-05-22 CL CL2014001349A patent/CL2014001349A1/es unknown
- 2014-06-13 CR CR20140279A patent/CR20140279A/es unknown
- 2014-06-16 CO CO14130059A patent/CO6990666A2/es unknown
- 2014-06-18 IN IN4582CHN2014 patent/IN2014CN04582A/en unknown
- 2014-06-18 ZA ZA2014/04481A patent/ZA201404481B/en unknown
- 2014-06-20 EC ECIEPI20145992A patent/ECSP14005992A/es unknown
-
2015
- 2015-03-27 HK HK15103143.3A patent/HK1202444A1/xx unknown
Also Published As
Publication number | Publication date |
---|---|
PE20141941A1 (es) | 2014-12-28 |
US20140348838A1 (en) | 2014-11-27 |
ZA201404481B (en) | 2016-01-27 |
CN104203278A (zh) | 2014-12-10 |
ECSP14005992A (es) | 2015-06-30 |
DOP2014000111A (es) | 2014-07-15 |
PH12014501138A1 (en) | 2014-08-04 |
CA2856582A1 (en) | 2013-05-30 |
WO2013078135A2 (en) | 2013-05-30 |
HK1202444A1 (en) | 2015-10-02 |
CR20140279A (es) | 2014-08-04 |
JP2015500206A (ja) | 2015-01-05 |
GT201400099A (es) | 2015-03-23 |
CO6990666A2 (es) | 2014-07-10 |
IL232674A0 (en) | 2014-07-31 |
SG11201402533YA (en) | 2014-09-26 |
EP2782601A4 (en) | 2015-09-16 |
AU2012340878A1 (en) | 2014-06-12 |
WO2013078135A3 (en) | 2014-09-04 |
BR112014012121A2 (pt) | 2019-09-24 |
MX2014006160A (es) | 2014-10-24 |
KR20140097430A (ko) | 2014-08-06 |
RU2014125220A (ru) | 2015-12-27 |
EP2782601A2 (en) | 2014-10-01 |
IN2014CN04582A (es) | 2015-09-18 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CL2014001349A1 (es) | Composición que comprende una inmunoglobulina con dos dominios variables dirigida contra il-1a/ß o una porción del antígeno de esta, la cual tiene características farmacocinéticas específicas; y uso de la composición para tratar o prevenir osteoartritis, dolor o un trastorno donde la actividad de il-1 resulta perjudicial. | |
CL2008000058A1 (es) | Formulacion que comprende un anticuerpo anti-il13, un criprotector, y una solucion amortiguadora; composicion farmaceutica que la comprende; metodo para tratar un trastorno relacionado con il13; y formas farmaceuticas que la comprenden. | |
BR112012003792A2 (pt) | gel tópico, e, uso do gel tópico. | |
EA202090031A2 (ru) | Человеческие антитела против gfr3 и способы их применения | |
EA201690206A1 (ru) | Терапевтически активные соединения и способы их применения | |
CL2015000028A1 (es) | Inmunoconjugado que comprende un anticuerpo anti-cd79b unido a un agente citotóxico derivado de nemorrubicina; formulación farmacéutica que lo comprende; y uso para tratar cáncer cd79b positivo. | |
EA201791007A3 (ru) | Соединения и их применения для модуляции гемоглобина | |
CL2013003639A1 (es) | Compuestos inhibidores de metaloenzimas; composición que comprende dichos compuestos; uso de la composición para tratar o prevenir una enfermedad asociada a metaloenzimas en plantas; uso para inhibir metaloenzimas en microorganismos y tratar un trastorno fúngico en plantas. | |
BR112012028764A2 (pt) | anticor-pos antifgfr2 | |
CL2013000238A1 (es) | Uso de inhibores de la succinato deshidrogenasa y/o inhibidores del complejo iii para mejorar la relacion entre microorganismos dañinos y beneficiosos. | |
EA201790882A1 (ru) | Способы и композиции для терапии рака печени | |
BRPI0817811A2 (pt) | Xilanases, ácidos nucleicos que codificam as mesmas e métodos para fabricação e uso das mesmas. | |
CL2007002879A1 (es) | Anticuerpo monoclonal contra nectina-2; celula de hibridoma que lo produce; composicion farmaceutica que lo comprende; y su uso para tratar cancer. | |
BR112013013781A2 (pt) | anticorpos humanizados para liv-1 e uso dos mesmos para tratar câncer | |
CL2012002217A1 (es) | Polipeptido aislado que comprende cuando menos un monómero de un solo dominio variable de un agente nb que se enlaza a dr5 humano; metodo para la prevencion y/o el tratamiento de un trastorno que se puede tratar mediante la mejora de la apoptosis celular. | |
CL2014003339A1 (es) | Anticuerpo humanizado anti-trka con propiedades inhibitorias mejoradas; composición que lo comprende; y uso para tratar el dolor. | |
CL2015000696A1 (es) | Tratamiento para artritis reumatoide | |
BR112013014522A2 (pt) | anticorpo anti-cd20 afucosilado e seu uso, composição e método para tratamento de um paciente que sofre de câncer | |
GT201200345A (es) | Compuestos heterocìclicos, su preparaciòn y su aplicaciòn terapèutica | |
CL2015001608A1 (es) | Formulación en solución de anticuerpo humanizado anti-il-23p19; y uso de formulación para tratar enfermedad autoinmune, enfermedad inflamatoria o trastorno proliferativo, particularmente psoriasis. | |
BR112012026707A2 (pt) | uso de um anticorpo anti-cd20 afucosilado, composição que compreende um anticorpo anti-cd20 afucosilado e método de tratamento de pacientes que sofrem de câncer por meio da administração de um anticorpo anti-cd20 afucosilado | |
CL2013000101A1 (es) | Anticuerpo cd37 para tratar tumor maligno de celulas b; composicion farmacéutica que lo comprende. | |
BR112013002441A2 (pt) | uso de um anticorpo anti-cd20 afucosilado, composição e método de tratamento de paciente que sofre de câncer | |
CL2014001021A1 (es) | Compuestos heterociclicos sustituidos con 1,3 diarilo; composicion que lo comprende; y su uso para controlar una plaga de invertebrados. | |
CO6870047A2 (es) | Soporte basado en fibras celulósicas y/o sintéticas, método para producirlo y uso del soporte |